NCT07887750
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
StatusNot Yet Recruiting
PhasePhase 1/2
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period
Timeframe: Up to 28 days
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 2 years
Severity of TEAEs
Timeframe: Up to approximately 2 years
Secondary (10)
Concentration of REGN9220 in serum when given in combination with odronextamab
Concentration of odronextamab in serum when given in combination with REGN9220
Occurrence of Anti-Drug Antibodies (ADA) to REGN9220
Magnitude of ADA to REGN9220
Occurrence of ADA to odronextamab
Show 5 moreShow less
Magnitude of ADA to odronextamab
Best Overall Response (BOR)
Complete Response (CR)
Progression-Free Survival (PFS)
Duration Of Response (DOR)
Arms and interventions
REGN9220 + OdronextamabExperimental
Drugs: REGN9220, Odronextamab